%0 Journal Article
%A Iacovino, Luca Giacinto
%A Manzella, Nicola
%A Resta, Jessica
%A Vanoni, Maria Antonietta
%A Rotilio, Laura
%A Pisani, Leonardo
%A Edmondson, Dale Edward
%A Parini, Angelo
%A Mattevi, Andrea
%A Mialet-Perez, Jeanne
%A Binda, Claudia
%D 2020
%T Rational Redesign of Monoamine Oxidase A into a Dehydrogenase
to Probe ROS in Cardiac Aging
%U https://acs.figshare.com/articles/journal_contribution/Rational_Redesign_of_Monoamine_Oxidase_a_into_a_Dehydrogenase_to_Probe_ROS_in_Cardiac_Aging/12588168
%R 10.1021/acschembio.0c00366.s001
%2 https://acs.figshare.com/ndownloader/files/23553330
%K O 2 reactivity
%K K 305S
%K adenoviral vectors
%K K 305M
%K Rational Redesign
%K oxidative deamination
%K attenuate cardiomyocytes
%K mitochondrial-membrane flavoenzyme ...
%K wild-type enzyme
%K ROS levels
%K Lys 305
%K k cat values
%K Monoamine Oxidase
%K frailty condition
%K expression increases
%K K 305Q variant
%K quinone electron acceptors
%K K m
%K Probe ROS
%K O 2
%K Cardiac Aging Cardiac senescence
%K H 2 O 2 production
%K oxidative stress
%K K 305M MAO
%K senescence markers
%K K 305M variant
%K MAO inhibitors
%X Cardiac senescence
is a typical chronic frailty condition in the
elderly population, and cellular aging is often associated with oxidative
stress. The mitochondrial-membrane flavoenzyme monoamine oxidase A
(MAO A) catalyzes the oxidative deamination of neurotransmitters,
and its expression increases in aged hearts. We produced recombinant
human MAO A variants at Lys305 that play a key role in O2 reactivity leading to H2O2 production. The
K305Q variant is as active as the wild-type enzyme, whereas K305M
and K305S have 200-fold and 100-fold lower kcat values and similar Km. Under
anaerobic conditions, K305M MAO A was normally reduced by substrate,
whereas reoxidation by O2 was much slower but could be
accomplished by quinone electron acceptors. When overexpressed in
cardiomyoblasts by adenoviral vectors, the K305M variant showed enzymatic
turnover similar to that of the wild-type but displayed decreased
ROS levels and senescence markers. These results might translate into
pharmacological treatments as MAO inhibitors may attenuate cardiomyocytes
aging.
%I ACS Publications